Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN, TANER; Efe, Orhan; Hasirci, Ahmet; Demirci, Fatih; Buyukhatipoglu, Hakan; Balakan, Ozan; Sarici, Furkan; KERTMEN, NEYRAN; Esin, Ece; AKIN, SERKAN; ATEŞ, ÖZTÜRK; AKSOY, SERCAN; SEVER, ALİ; Altundag, Kadri

doi:10.5301/tj.5000332

Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

Copy For Citation

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., ...More

TUMORI J, vol.101, no.4, pp.418-423, 2015 (SCI-Expanded)

Publication Type: Article / Article
Volume: 101 Issue: 4
Publication Date: 2015
Doi Number: 10.5301/tj.5000332
Journal Name: TUMORI J
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.418-423
Hacettepe University Affiliated: Yes

Abstract

Aims and Background: Capecitabine is a potent and safe agent that can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of capecitabine monotherapy as a first-line treatment in human epidermal receptor 2 (HER2)-negative patients with MBC.